Pharma Tech Benefits Now Reach Non-MSMEs

The Indian pharmaceutical industry is undergoing a major transformation as the government has revamped the Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS) to support drug companies in upgrading their facilities to produce medicines conforming to global standards. The scheme now extends beyond MSMEs to pharmaceutical manufacturing units with a turnover of less than Rs 500 crore that require technology and quality upgradation.

Why PTUAS is important

The PTUAS scheme was launched in 2016 to help MSMEs in the pharma sector to upgrade their technology and quality standards to meet the revised Schedule-M and WHO-GMP norms. These norms are essential to ensure the safety, efficacy and quality of pharmaceutical products manufactured in the country. The scheme also aimed to enhance the competitiveness of the Indian pharma industry in the global market, which is expected to reach USD 1.5 trillion by 2023.

However, the scheme had some limitations, such as a credit-linked approach, a narrow scope of eligible activities, and a lack of integration with state government schemes. These factors limited the adoption and impact of the scheme among the pharma units.

How PTUAS has been revamped

The Department of Pharmaceuticals (DoP) has revamped the PTUAS scheme to address these limitations and make it more attractive and accessible for the pharma units. The key features of the revamped scheme are:

  • The eligibility criteria has been expanded to include any pharma manufacturing unit with a turnover of less than Rs 500 crore that needs technology and quality upgradation. Preference however remains for MSMEs, supporting smaller players in achieving high-quality manufacturing standards.
  • The financing options have been made more flexible, emphasizing subsidies on reimbursement basis, over traditional credit-linked approach. This flexibility is designed to diversify the financing options of the participating units, facilitating a more widespread adoption of the scheme.
  • The scope of eligible activities has been broadened to support a wider range of technological upgrades, such as HVAC systems, water and steam utilities, testing laboratories, stability chambers, clean room facilities, effluent treatment, waste management etc. ensuring comprehensive support for participating units.
  • The scheme allows integration with state government schemes, enabling units to benefit from additional top-up assistance. This collaborative approach aims to maximise support for the pharma industry in their technology upgradation efforts.
  • The scheme introduces a robust verification mechanism through a project management agency, ensuring transparency, accountability and the efficient allocation of resources.

What are the benefits of PTUAS

The revamped PTUAS scheme is expected to have multiple benefits for the pharma industry and the public health system. Some of these benefits are:

  • The scheme will help the pharma units to upgrade their technology and quality standards to meet the revised Schedule-M and WHO-GMP norms, enhancing the quality and safety of pharmaceutical products manufactured in the country.
  • The scheme will also help the pharma units to improve their productivity, efficiency and profitability by adopting modern and innovative technologies and processes.
  • The scheme will enable the pharma units to access new markets and opportunities by complying with global standards and regulations. India is already one of the leading exporters of generic drugs and vaccines, accounting for 20% of the global supply volume and 60% of global vaccine production.
  • The scheme will boost the competitiveness and innovation of the Indian pharma industry in the global arena, contributing to its growth and development. From FY18 to FY22, the Indian pharmaceutical industry logged an average growth rate of 9.47% to USD 42.34 billion, primarily driven by an increase in exports and a rise in the domestic market. It is expected that the Pharma sector is likely to reach USD 65 billion industry by 2024 and USD 120 billion by 2030.
  • The scheme will ultimately benefit the public health system by ensuring the availability of affordable, safe and effective medicines for various diseases and conditions.

The revamped PTUAS scheme is a welcome step by the government to support the pharma industry in its technology and quality upgradation journey. The scheme will help the industry to overcome its challenges and leverage its potential to become a global leader in pharmaceutical manufacturing.

Recent Blog : Govt Rejects Vedanta HZL Demerger Proposal

Share:

MORE STORIES

## Navigating the AI Revolution: 5 Trending Google Ads Topics for Marketers As Google Ads continues its rapid evolution, staying ahead of the curve is paramount for digital marketers. The platform’s increasing reliance on artificial intelligence, shifting privacy landscapes, and the introduction of new campaign types are creating a fresh set of challenges and opportunities. Here are five top trending blog topics that delve into the most critical areas of Google Ads today. ### 1. The Rise of the Machines: Mastering AI-Powered Campaign Types Google is unequivocally betting on AI to drive the future of its advertising platform. A key area of focus for marketers is understanding and mastering AI-driven campaign types like Performance Max and Demand Gen. These campaigns automate targeting, bidding, and ad creation across Google’s entire inventory. A deep dive into strategies for providing the right inputs to these “black box” models, interpreting their performance, and understanding how to guide the AI for optimal results is a crucial topic for advertisers looking to succeed in this new era. ### 2. Beyond the Click: Navigating the New Landscape of Measurement and Attribution With the impending deprecation of third-party cookies and a growing emphasis on user privacy, the way advertisers measure success is undergoing a fundamental shift. This has propelled topics like enhanced conversions, consent mode, and the integration of first-party data to the forefront. Marketers are actively seeking guidance on how to implement these privacy-centric measurement solutions to gain a more accurate and holistic view of their campaign performance in a world without granular user tracking. ### 3. Creative is the New Targeting: Leveraging AI for Compelling Ad Experiences In an automated world, the creative has become a key differentiator. Google is investing heavily in AI-powered tools that can generate and optimize ad copy, images, and videos. Blog posts that explore how to effectively use these generative AI features to create a high volume of diverse and engaging ad creatives are gaining significant traction. This includes best practices for providing creative inputs, A/B testing AI-generated assets, and ensuring brand consistency across automated campaigns. ### 4. The Evolution of Search: Adapting to a More Conversational and Visual SERP The traditional keyword-based search is evolving. Users are increasingly employing longer, more conversational queries, and Google is responding with a more visual and AI-driven search engine results page (SERP). This shift requires a re-evaluation of traditional keyword research and bidding strategies. Trending discussions revolve around how to adapt to this new reality, including the role of broad match keywords, the importance of high-quality creative in visual search formats, and strategies for capturing intent in a more conversational search landscape. ### 5. Future-Proofing Your Strategy: The Growing Importance of a Full-Funnel Approach As automation takes over many of the manual levers within Google Ads, the focus is shifting towards a more strategic, full-funnel marketing approach. Advertisers are looking for insights on how to effectively use different Google Ads campaign types to guide users through the entire customer journey, from initial awareness to final conversion and retention. This includes discussions on how to structure campaigns to complement each other, allocate budgets across the funnel, and measure the impact of upper-funnel activities on bottom-line results.

Google Ads is in the midst of a quiet revolution—one driven by artificial intelligence, privacy-first regulations, and a rapidly changing search landscape. For digital marketers,

Send Us A Message